SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* WALTON ALAN G (Last) (First) (Middle) 315 POST ROAD WEST (Street) WESTPORT CT 06880 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol ACADIA PHARMACEUTICALS INC [ ACAD ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 06/15/2007
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$15.02	06/15/2007		A		10,000		(1)	06/14/2017	Common Stock	10,000	$0	10,000	D
Stock Option (Right to Buy)	$15.02	06/15/2007		A		3,994		(1)	06/14/2017	Common Stock	3,994	(2)	3,994	D

Explanation of Responses:

1. One-fourth of the shares subject to the Stock Option shall vest and become exercisable at the end of each three-month period following June 15, 2007.

2. The Reporting Person has elected to convert annual retainer fees of $20,000 into a stock option under the terms of the Issuer's Outside Director Compensation Program.

Remarks:

	/s/ Raymond Charest, as attorney-in-fact for Alan G. Walton	06/19/2007
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

EXHIBIT A

POWER OF ATTORNEY

	KNOW ALL MEN BY THESE PRESENTS, that each
person whose signature appears below hereby
constitutes and appoints Raymond Charest, Alexia
Pearsall and Jonathan J. Fleming, and each of
them, with full power to act without the other,
his true and lawful attorney-in-fact and agent,
with full power of substitution, for him and in
his name, place and stead, in any and all
capacities (until revoked in writing) to sign
any and all instruments, certificates and
documents required to be executed on behalf of
himself as an individual or in his capacity as
a general partner or authorized signatory, as
the case may be, on behalf of any of Oxford
Bioscience Partners IV L.P., mRNA II L.P.,
or OBP Management IV L.P., pursuant to
section 13 or 16 of the Securities Exchange
Act of 1934, as amended (the "Exchange Act"),
and any and all regulations promulgated
thereunder and to file the same, with all
exhibits thereto, and any other documents in
connection therewith, with the Securities and
Exchange Commission, and with any other entity
when and if such is mandated by the Exchange
Act or by the By-laws of the National Association
of Securities Dealers, Inc., granting unto said
attorney-in-fact and agent full power and
authority to do and perform each and every act and
thing requisite and necessary fully to all intents
and purposes as he might or could do in person
thereby ratifying and confirming all that said
attorney-in-fact and agent, or his substitute or
substitutes, may lawfully do or cause to be done
by virtue hereof, or may have done in connection
with the matters described above.

IN WITNESS WHEREOF, this Power of Attorney has
been signed as of the 8th day of April, 2004.


OXFORD BIOSCIENCE PARTNERS IV L.P.
by its General Partner, OBP MANAGEMENT IV L.P.

By: /s/ Jonathan Fleming
Name:  Jonathan J. Fleming
Title:  General Partner


MRNA FUND II L.P.
By its General Partner, OBP MANAGEMENT IV L.P.
By: /s/ Jonathan Fleming
Name:  Jonathan J. Fleming
Title:  General Partner


OBP MANAGEMENT IV L.P.
By:/s/ Jonathan Fleming
Name:  Jonathan J. Fleming
Title:  General Partner



/s/ Jeffrey T. Barnes
Jeffrey T. Barnes



/s/ Mark P. Carthy
Mark P. Carthy



/s/ Jonathan J. Fleming
Jonathan J. Fleming



/s/ Michael E. Lytton
Michael E. Lytton



/s/ Alan G. Walton
Alan G. Walton